Last reviewed 2026-04-23 · How we verify

Half dose of MVC-COV1901

Medigen Vaccine Biologics Corp. · Phase 2 active Biologic

Half dose of MVC-COV1901 is a Biologic drug developed by Medigen Vaccine Biologics Corp.. It is currently in Phase 2 development.

At a glance

Generic name	Half dose of MVC-COV1901
Sponsor	Medigen Vaccine Biologics Corp.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Half dose of MVC-COV1901 CI brief — competitive landscape report
Half dose of MVC-COV1901 updates RSS · CI watch RSS
Medigen Vaccine Biologics Corp. portfolio CI

Frequently asked questions about Half dose of MVC-COV1901

What is Half dose of MVC-COV1901?

Half dose of MVC-COV1901 is a Biologic drug developed by Medigen Vaccine Biologics Corp..

Who makes Half dose of MVC-COV1901?

Half dose of MVC-COV1901 is developed by Medigen Vaccine Biologics Corp. (see full Medigen Vaccine Biologics Corp. pipeline at /company/medigen-vaccine-biologics-corp).

What development phase is Half dose of MVC-COV1901 in?

Half dose of MVC-COV1901 is in Phase 2.

Manufacturer: Medigen Vaccine Biologics Corp. — full pipeline
Compare: Half dose of MVC-COV1901 vs similar drugs
Pricing: Half dose of MVC-COV1901 cost, discount & access